Lumretuzumab

Lumretuzumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target ERBB3
Clinical data
ATC code none
Identifiers
CAS Number 1448327-63-6
ChemSpider none
Chemical and physical data
Formula C6512H10064N1736O2052S44
Molar mass 146.9 kDa

Lumretuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]

This drug was developed by Genentech/Roche.

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Lumretuzumab, American Medical Association.
  2. World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.